Late-onset neutropenia and neurological relapse,during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder

Abstract

Late-onset neutropenia after rituximab therapy (LONART) is defined as a fall in the absolute neutrophil count below 500/mm³ at least 3 weeks after rituximab infusion, in the absence of any other explanation. LONART is rare during dysimmune conditions but can be life-threatening. We report on two patients with LONART and associated neurological relapse occurring in myelin oligodendrocyte glycoprotein (MOG)-antibody spectrum disorders. Rituximab was reintroduced in one patient, while the second patient was switched to tocilizumab. LONART can occur during anti-MOG spectrum disorders. Neurologists should be aware of this rare and treatable complication. Regular monitoring of blood cell counts is needed, and patients should be informed of the need to consult their physician if symptoms of infection appear.

Keywords

Rituximab late onset neutropenia anti-myelin oligodendrocyte glycoprotein antibodies neuromyelitis optica spectrum disorders

Get full access to this article

View all access options for this article.

References

Moore

DC.

Drug-induced neutropenia: A focus on rituximab-induced late-onset neutropenia. P T 2016; 41: 765–768.

Weng

Negrin

Lavori

et al . Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2010; 28: 279–284.

Wolach

Shpilberg

Lahav

Neutropenia after rituximab treatment: New insights on a late complication. Curr Opin Hematol 2012; 19: 32–38.

Kronbichler

Windpessl

Pieringer

et al . Rituximab for immunologic renal disease: What the nephrologist needs to know. Autoimmun Rev 2017; 16: 633–643.

Tesfa

Palmblad

Late-onset neutropenia following rituximab therapy: Incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011; 4: 619–625.

Salmon

Cacoub

Combe

et al . Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: Data from the autoimmunity and rituximab registry. RMD Open 2015; 1: e000034.

Tesfa

Ajeganova

Hagglund

et al . Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63: 2209–2214.

European Medicines Agency. Ocrevus: Assessment report. EMA/790835/201, 9 November 2017. Committee for Medicinal Products for Human Use (CHMP). London, UK: European Medicines Agency.

Knight

Sundstrom

Borjesson

et al . Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol 2016; 45: 404–407.

10.

Jarius

Ruprecht

Kleiter

et al . MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13: 280.

11.

Grant

Wilson

Dunleavy

Neutropenia associated with rituximab therapy. Curr Opin Hematol 2011; 18: 49–54.

12.

Besada

Koldingsnes

Nossent

Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: A case review analysis from a single center. QJM 2012; 105: 545–550.